Table 2 Prognostic analysis of APOL isoforms for patient survival in TCGA cohort.

From: Identification and validation of candidate clinical signatures of apolipoprotein L isoforms in hepatocellular carcinoma

Type	Variables	Patients	Overall survival
Type	Variables	(n = 370)	No. of event	MST (days)	HR (95%CI)	Crude P value	HR (95%CI)	Adjusted P value^Ѱ
OS	APOL1					0.088		0.123
	Low expression	185	68	1372	Reference		Reference
	High expression	185	62	2116	0.740 (0.523–1.046)		0.735 (0.498–1.087)
	APOL2					0.526		0.709
	Low expression	185	62	1423	Reference		Reference
	High expression	185	68	1791	0.893 (0.628–1.268)		0.927 (0.624–1.378)
	APOL3					0.107		0.126
	Low expression	185	68	1397	Reference		Reference
	High expression	185	62	1791	0.752 (0.533–1.063)		0.737 (0.499–1.090)
	APOL4					0.385		0.961
	Low expression	185	59	2542	Reference		Reference
	High expression	185	71	1624	1.166 (0.825–1.648)		1.010 (0.682–1.494)
	APOL5					0.162		0.974
	Low expression	185	71	1490	Reference		Reference
	High expression	185	59	2116	0.781 (0.552–1.104)		0.994 (0.675–1.462)
	APOL6					0.014		0.004
	Low expression	185	72	1423	Reference		Reference
	High expression	185	58	2116	0.646 (0.457–0.914)		0.565 (0.383–0.835)
RFS	APOL1					0.478		0.224
	Low expression	159	71	875	Reference		Reference
	High expression	159	68	903	0.886 (0.635–1.237)		0.771 (0.507–1.172)
	APOL2					0.782		0.836
	Low expression	164	73	893	Reference		Reference
	High expression	154	66	879	0.954 (0.683–1.332)		0.956 (0.624–1.465)
	APOL3					0.026		0.026
	Low expression	159	77	776	Reference		Reference
	High expression	159	62	1286	0.684 (0.489–0.956)		0.619 (0.405–0.945)
	APOL4					0.374
	Low expression	162	73	776	Reference		Reference	0.050
	High expression	156	66	903	0.859 (0.614–1.201)		0.647 (0.409–1.001)
	APOL5					0.359		0.605
	Low expression	156	71	701	Reference		Reference
	High expression	162	68	1032	0.856 (0.613–1.194)		0.895 (0.588–1.362)
	APOL6					0.088		0.118
	Low expression	158	71	776	Reference		Reference
	High expression	160	68	912	0.748 (0.536–1.044)		0.715 (0.470–1.089)

Ѱ: P values were adjusted for HBV infection, tumor stage, and radical resection in OS and were adjusted for HBV infection, tumor stage, radical resection and vascular invasion in RFS; Bold indicates significant P values.
NA: not available; MST: median survival time; HR: hazard ratio; 95%CI: 95% confidence interval; OS: overall survival; RFS: recurrence-free survival.

Back to article page

Table 2 Prognostic analysis of APOL isoforms for patient survival in TCGA cohort.

Search

Quick links